Blood binding of selezen (imidazole salicylate) in man.
The interactions of selezen (imidazole salicylate) with human blood components were studied by equilibrium dialysis. These interactions were limited to the binding of salicylate to human serum albumin (HSA). The binding was saturable and involved several classes of binding sites with different association constants. A competition study indicated that salicylic acid at high concentration was able to displace warfarin and digitoxin but not glibenclamide from their HSA sites. On the other hand, selezen serum binding was decreased in renal impaired patients and this result was probably linked to the decreases in HSA concentration. So the use of small dosage regimens of selezen to these patients can be proposed. The same recommendation may be done for cirrhotic patients, where the decrease of selezen binding percentage was observed and due to both hypoalbuminemia and hyperbilirubinemia.
Zini
R
R
Laboratoire de pharmacologie UFR de Médecine de Paris XII, Créteil, France.
Morin
D
D
Acuto
G C
GC
Bianchini
C
C
de Santis
F
F
Tillement
J P
JP
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood*; D001798:Blood Proteins / Q000302:isolation & purification / Q000378:metabolism*; D002908:Chronic Disease; D003956:Dialysis; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood; D008107:Liver Diseases / Q000097:blood; D012459:Salicylates / Q000097:blood*; D020156:Salicylic Acid
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001798:Blood Proteins; D007093:Imidazoles; D012459:Salicylates; C043292:imidazole-2-hydroxybenzoate; D020156:Salicylic Acid